Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug;26(8):600-614.
doi: 10.1038/s41580-025-00842-3. Epub 2025 Apr 9.

p53-regulated non-apoptotic cell death pathways and their relevance in cancer and other diseases

Affiliations
Review

p53-regulated non-apoptotic cell death pathways and their relevance in cancer and other diseases

Yanqing Liu et al. Nat Rev Mol Cell Biol. 2025 Aug.

Abstract

Programmed cell death is a mechanism that is crucial for numerous physiological and pathological processes. Whereas p53-mediated apoptosis is a major cell death pathway in cancer, accumulating evidence indicates that p53 also has crucial roles in controlling different non-apoptotic cell death (NACD) pathways, including ferroptosis, necroptosis, pyroptosis, autophagy-dependent cell death, entotic cell death, parthanatos and paraptosis, and may regulate PANoptosis, cuproptosis and disulfidptosis. Notably, the function of p53 in these NACDs substantially contributes to its biological effects, particularly in cancer development and other pathological processes. In this Review, we discuss recent advances in understanding the roles and underlying mechanisms of p53-mediated NACDs, focusing on ferroptosis, necroptosis and pyroptosis. We discuss the complex and distinct physiological settings in which NACDs are regulated by p53, and potential targeting of p53-regulated NACDs for the treatment of cancer and other human diseases. Finally, we highlight several important questions concerning p53-regulated NACDs that warrant further investigation.

PubMed Disclaimer

Conflict of interest statement

Competing interests: B.R.S. is an inventor on patents and patent applications involving ferroptosis; he has co-founded and serves as a consultant to ProJenX, Inc. and Exarta Therapeutics; holds equity in Sonata Therapeutics; serves as a consultant to Weatherwax Biotechnologies Corporation and Akin Gump Strauss Hauer & Feld LLP. X.J. is an inventor on patents related to autophagy and cell death, and holds equity of and consults for Exarta Therapeutics and Lime Therapeutics. The other authors declare no competing interests.

Similar articles

Cited by

References

    1. Liu, Y. Q., Su, Z. Y., Tavana, O. & Gu, W. Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell 42, 946–967 (2024). - PMC - PubMed
    1. Hassin, O. & Oren, M. Drugging p53 in cancer: one protein, many targets. Nat. Rev. Drug Discov. 22, 127–144 (2023). - PubMed
    1. Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M. & Wiman, K. G. Pharmacological reactivation of p53 in the era of precision anticancer medicine. Nat. Rev. Clin. Oncol. 21, 106–120 (2024). - PubMed
    1. Brady, C. A. et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 145, 571–583 (2011). - PMC - PubMed
    1. Li, T. Y. et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149, 1269–1283 (2012). - PMC - PubMed

Substances